As of June 21, 2025, Antisense Therapeutics Ltd (ANP.AX) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Antisense Therapeutics Ltd's Forward P/E to Peers
To better understand Antisense Therapeutics Ltd's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Antisense Therapeutics Ltd (ANP.AX) | - |
| Zelira Therapeutics Ltd (ZLD.AX) | 376.24 |
| Neuren Pharmaceuticals Ltd (NEU.AX) | 95.95 |
| Little Green Pharma Ltd (LGP.AX) | 21.78 |
| IDT Australia Ltd (IDT.AX) | 18.63 |
| Acrux Ltd (ACR.AX) | 2.43 |
Compared to its competitors, Antisense Therapeutics Ltd's Forward P/E is difficult to compare due to insufficient data.